ATE73331T1 - Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. - Google Patents

Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.

Info

Publication number
ATE73331T1
ATE73331T1 AT86107614T AT86107614T ATE73331T1 AT E73331 T1 ATE73331 T1 AT E73331T1 AT 86107614 T AT86107614 T AT 86107614T AT 86107614 T AT86107614 T AT 86107614T AT E73331 T1 ATE73331 T1 AT E73331T1
Authority
AT
Austria
Prior art keywords
treatment
autism
tetrahydrobiopterins
medication
children
Prior art date
Application number
AT86107614T
Other languages
German (de)
English (en)
Inventor
Hiroshi Naruse
Masashi Takesada
Osamu Hayaishi
Yasuyoshi Watanabe
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE73331T1 publication Critical patent/ATE73331T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
AT86107614T 1985-06-04 1986-06-04 Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. ATE73331T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP60121347A JPS61277618A (ja) 1985-06-04 1985-06-04 自閉症治療剤
EP86107614A EP0209689B1 (en) 1985-06-04 1986-06-04 Use of tetrahydrobiopterins in the preparation of a medicament for the treatment of infantile autism

Publications (1)

Publication Number Publication Date
ATE73331T1 true ATE73331T1 (de) 1992-03-15

Family

ID=14809022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86107614T ATE73331T1 (de) 1985-06-04 1986-06-04 Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.

Country Status (5)

Country Link
US (2) US4778794A (cg-RX-API-DMAC7.html)
EP (1) EP0209689B1 (cg-RX-API-DMAC7.html)
JP (1) JPS61277618A (cg-RX-API-DMAC7.html)
AT (1) ATE73331T1 (cg-RX-API-DMAC7.html)
DE (1) DE3684190D1 (cg-RX-API-DMAC7.html)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
CA1334654C (en) * 1987-11-30 1995-03-07 Masayasu Kurono Intermediates for synthesizing bh _and its derivatives
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
ES2177654T3 (es) 1994-08-05 2002-12-16 Suntory Ltd Remedio contra la degeneracion espinocerebelosa.
KR20060094988A (ko) 1996-08-30 2006-08-30 다이이치 아스비오파마 가부시키가이샤 질소 산화물 합성효소 (ｎｏｓ)의 기능 저하에 의해유발되는 질환의 예방 또는 치료제
JP2002501616A (ja) 1997-05-19 2002-01-15 リプリゲン コーポレーション 自閉的症候群を鑑別診断および治療する際の助けとするための方法
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
EP1004308B1 (en) 1998-02-27 2005-05-11 Daiichi Suntory Pharma Co., Ltd. Preventives or remedies for drug-induced renal disturbance
JP4306825B2 (ja) * 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
WO2001079837A1 (en) * 2000-04-12 2001-10-25 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US20060110325A1 (en) * 2003-02-21 2006-05-25 Hinz Martin C Serotonin and catecholamine segment optimization technology
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
WO2003079886A2 (en) * 2002-03-21 2003-10-02 Hinz Martin C Serotonin and catecholamine system segment optimization techonology
DE10260263A1 (de) * 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AU2012200512C1 (en) * 2003-11-17 2020-04-30 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
PL1708690T3 (pl) * 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
WO2005113833A2 (en) * 2004-05-21 2005-12-01 Duke University Polymorphism in tryptophan hydroxylase-2 controls brain serotonin synthesis
CA2601716C (en) * 2004-06-25 2011-05-31 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
MX2007005039A (es) * 2004-11-17 2007-06-19 Biomarin Pharm Inc Formulacion de tableta estable.
EP1819340A2 (en) * 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US20070034214A1 (en) * 2005-08-12 2007-02-15 Dochniak Michael J Method to affect the development of autism spectrum disorders
EP1965803A1 (en) * 2005-12-05 2008-09-10 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
US20100234385A1 (en) * 2006-03-20 2010-09-16 Kaneka Corporation Compsition Containing Biopterin and Method for Using The Same
EP2114944A2 (en) * 2007-01-12 2009-11-11 BioMarin Pharmaceutical Inc. Tetrahydrobiopterin prodrugs
US20100009997A1 (en) * 2007-01-12 2010-01-14 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug
LT2545939T (lt) 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
JP2011508775A (ja) 2008-01-03 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド Ｂｈ４応答性状態を治療するためのプテリン類似体
US20110104074A1 (en) * 2008-06-18 2011-05-05 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
TR201910287T4 (tr) * 2008-08-12 2019-07-22 Orpha Swiss Gmbh Tetrahidrobiopterin ihtiva eden farmasötik dozaj şekli.
JP5066756B2 (ja) * 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
RU2661033C9 (ru) * 2011-03-01 2018-10-23 Дифарма С.А. Стабильные композиции тетрагидробиоптерина
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
EP2847169A4 (en) 2012-05-07 2015-09-30 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
WO2014041446A2 (en) * 2012-09-17 2014-03-20 Mahesh Kandula Compositions and methods for the treatment of metabolic diseases
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5976086A (ja) * 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
AU572792B2 (en) * 1982-09-20 1988-05-19 Wellcome Foundation Limited, The 2-amino, 4-oxo-pteridine derivatives
GB8318833D0 (en) * 1983-07-12 1983-08-10 Wellcome Found Chemical compounds

Also Published As

Publication number Publication date
EP0209689A2 (en) 1987-01-28
US4920122A (en) 1990-04-24
EP0209689B1 (en) 1992-03-11
DE3684190D1 (de) 1992-04-16
JPH0380127B2 (cg-RX-API-DMAC7.html) 1991-12-24
US4778794A (en) 1988-10-18
EP0209689A3 (en) 1989-12-20
JPS61277618A (ja) 1986-12-08

Similar Documents

Publication Publication Date Title
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
UA41297C2 (uk) Похідні індолу, фармацевтична композиція і спосіб лікування
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ATE122885T1 (de) Mittel zur behandlung von herzerkrankungen.
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
DE3855113D1 (de) Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69129563D1 (de) Epidermis-Wachstumsfaktor als Arzneimittel zur Wiederherstellung der Neuronen der Substantia nigra in der Behandlung nervenzerstörender Störungen
ATE3552T1 (de) Verfahren zur herstellung von phosphono-hydroxy- essigsaeure und salzen derselben sowie diese enthaltende autivirale mittel.
ATE110568T1 (de) Pharmazeutisches präparat zur behandlung des katarakts.
FR2658190B1 (fr) Esters d'aminoacides de l'hydroquinone, leur procede de preparation et compositions pharmaceutiques ou cosmetiques les contenant.
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
DE3584426D1 (de) Verwendung von spergualin oder eines seiner pharmazeutisch akzeptablen salze zur herstellung eines transplantation-immunitaet unterdrueckenden und anti-allergischen mittels.
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
DE59107405D1 (de) Ein Imidazobenzodiazepin zur Behandlung von Schlafstörungen
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee